Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Amryt has signed an exclusive distribution agreement with GryNumber Health (GryNumber) for the distribution of Lojuxta (lomitapide) in Central and Eastern Europe (CEE).
Subscribe to our email newsletter
GryNumber is one of the leading healthcare consultancy and distribution companies in the region, with many years of experience.
The agreement covers the distribution of Lojuxta across Austria, Croatia, Czech Republic, Estonia, Finland, Hungary, Latvia, Lithuania, Poland, Slovakia and Slovenia.
Lojuxta is a treatment for the rare, life-threatening, genetic cholesterol disorder Homozygous Familial Hypercholesterolemia ("HoFH") and Amryt estimates that there are approximately 100 patients with HoFH in these countries, with requests for access to Lojuxta made by clinicians throughout the region.
Amryt has signed distribution contracts covering Saudi Arabia and Switzerland recently as it continues to develop sales of Lojuxta, having acquired exclusive marketing rights to the drug across certain territories in December 2016.
Amryt Pharma CEO Joe Wiley said: "GryNumber Health has a well-established presence in, and significant experience of, the healthcare markets in Central and Eastern Europe and therefore is an ideal partner for us in the region. We are delighted to have signed this exclusive distribution agreement as we look to provide access to Lojuxta to patients suffering from HoFH across our licensed territories."